A Phase 2 study of LN-145 alone or in combination with durvalumab in PD-1/PDL-1 naive NSCLC patients

Trial Profile

A Phase 2 study of LN-145 alone or in combination with durvalumab in PD-1/PDL-1 naive NSCLC patients

Planning
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2017

At a glance

  • Drugs LN 145 (Primary) ; Durvalumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 19 Dec 2017 New trial record
    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, this trial will initiate in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top